Cambridge cancer firm lines up $174m bonanza

Medical technology from Cambridge UK cancer business Sentinel Oncology is being developed and commercialised by US company Oncothyreon in a collaboration that could bring the Science Park firm mega-millions. Oncothyreon has struck the deal to help develop Sentinel’s Checkpoint Kinase 1 (Chk1) programme: Chk1 inhibition selectively sensitises cancer cells to radiotherapy and chemotherapy.

Business Weekly